Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Article Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeSubmitted by Jeffrey Neal Johnson. Published: 12/31/2025. 
Key Points - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold. Nowhere is this more evident than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finishes the year as one of the most unloved assets in the S&P 500. For the casual observer, the pessimism seems justified. The firm has spent the last two years battling a perfect storm: COVID-19 product revenue evaporated faster than anticipated, several high-profile pipeline candidates failed in clinical trials, and activist investors waged a public campaign against management. Buy This AI Stock Tomorrow Morning?
A former hedge fund manager known for spotting early winners is sounding the alarm once again. He called Netflix at $7.78 (up 4,200% since), Apple at $0.35 (up 20,000%), and Amazon at a split-adjust $2.41 (up 3,200%). Now he's turning his focus to a little-known AI company that just earned a near-perfect score in his new proprietary stock grading system. In a brand-new presentation, he reveals the name, ticker symbol, and why this could be the smartest AI move of the year... especially if you're over 50. Click here to watch it before word gets out. However, smart investing often requires venturing where others refuse to go. With the exit of activist investor Starboard Value in November and a realistic reset of financial guidance, much of the worst appears to be behind the company. With the bad news largely priced in, Pfizer's stock has likely found a floor. As we enter 2026, Pfizer presents a rare scenario: a blue-chip company trading at a distressed price, paying a solid dividend while quietly rebuilding its future. The Mathematical Case: Why the Price Is Wrong For value investors, the argument for Pfizer is straightforward. The market is pricing the company as if its earnings will permanently shrink, creating a wide gap between the share price and the firm's cash-generating ability. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio (P/E) of roughly 8.6x. By comparison, the average pharmaceutical company trades at about 15x to 20x earnings, and high-growth peers such as Eli Lilly (NYSE: LLY) command materially higher multiples. A forward P/E near 8.6x implies minimal growth expectations. That sets a low bar: Pfizer doesn't need to pull off a miracle to see the stock rise. It only needs to demonstrate stability or modest growth. Any positive earnings surprise could prompt a multiple expansion as the market re-rates the shares closer to sector norms. The Dividend Shield While investors wait for a repricing, they are paid to hold the stock. - Annual Payout: $1.72 per share.
- Current Yield: Approximately 6.9%.
That yield is well above the S&P 500 average and functions as a margin of safety. Even if the share price remains flat through 2026, a near-7% dividend alone provides a baseline return that outpaces most savings accounts and many government bonds. Management is defending the payout with a $4 billion cost-saving initiative. By cutting administrative bloat and optimizing manufacturing, the company is preserving the cash flow needed to keep those quarterly checks flowing. The New Foundation: Oncology Takes the Lead The biggest criticism of Pfizer is the growth gap left by the decline of its COVID business. To fill that hole, the company has pivoted aggressively toward oncology. The Guided Missile Technology The crown jewel of Pfizer's 2023 Seagen acquisition is leadership in Antibody-Drug Conjugates (ADCs). Traditional chemotherapy is a broad-blast approach that harms both healthy and cancerous cells; ADCs are more like guided missiles, engineered to seek specific cancer cells and deliver a toxic payload directly, sparing healthy tissue. This strategy is producing results. The Seagen portfolio contributed approximately $3.4 billion in revenue in 2024, including about $2.75 billion in the first three quarters, driven by strong sales of Padcev for bladder cancer. Navigating the Bumps The road hasn't been perfectly smooth. In December 2025, Pfizer reported a safety signal related to Hympavzi involving a patient death during a trial extension. While that news rattled the stock briefly, it does not negate the broader thesis. The oncology portfolio is deep — more than 60 programs are in development — and Pfizer recently strengthened its pipeline by licensing a promising bispecific antibody from 3SBio, underscoring its effort to reload with potential blockbusters. Catching Up: The Strategy for Weight Loss In early 2025, Wall Street largely wrote Pfizer off in the lucrative weight-loss drug race after its internal pill, Danuglipron, failed to progress. But exiting the biggest medical trend of the decade was never an option. In late 2025, Pfizer re-entered the field through two strategic transactions. The Injectable Strategy (Metsera) In November, Pfizer acquired Metsera for roughly $7 billion, giving it immediate ownership of a next-generation injectable (MET-097i). Unlike current market leaders requiring weekly injections, this candidate may be administered monthly, offering patients a meaningful convenience advantage. The Oral Strategy (YaoPharma) Recognizing that many patients prefer pills, Pfizer also signed a licensing deal with YaoPharma for a small-molecule GLP-1 candidate, adding an oral option to its obesity playbook. Why This Matters Pfizer's current share price largely assigns no value to its obesity pipeline. With expectations at rock bottom, investors effectively hold a free option: any clinical wins from the Metsera or YaoPharma assets would be pure upside. Pfizer doesn't need to be first to market; it only needs to capture a meaningful slice of what could become a roughly $100 billion market. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 as a company in transition with a strengthened financial footing. Management has set a revenue floor of about $61 billion for 2026 — a realistic target that removes much of the uncertainty that plagued the stock. The investor equation is simple. At roughly $25 per share, downside is cushioned by a healthy dividend and a valuation at historic lows. The upside could be considerable: continued oncology growth or positive weight-loss drug data could trigger a sharp re-rating. Unloved stocks one year can become standout performers the next. With activist pressure eased and the balance sheet stabilized, Pfizer has moved from a falling knife to a potential foundational holding for value-oriented portfolios. For the company, 2026 may be the year the sleeping giant wakes up.
| 
